

Opioids are only effective to treat chronic* non-cancer pain (CNCP) in a small percentage of people.¹

- There is a **LACK OF ROBUST CLINICAL EVIDENCE** to support the long-term use of opioids in the treatment of CNCP.^{2,3}
- There are **ASSOCIATED HARMS** with the use of opioids, such as adverse drug reactions, long-term adverse effects and safety concerns in older people^{4,5}

Harms associated with opioids

Adverse drug reactions^{4,5**}

- | | |
|-----------------|--------------------------|
| ▪ Arrhythmias | ▪ Hyperhidrosis |
| ▪ Confusion | ▪ Hypotension |
| ▪ Constipation | ▪ Nausea and vomiting |
| ▪ Dizziness | ▪ Palpitations |
| ▪ Drowsiness | ▪ Respiratory depression |
| ▪ Dry mouth | ▪ Skin reactions |
| ▪ Euphoric mood | ▪ Urinary retention |
| ▪ Flushing | ▪ Vertigo |
| ▪ Hallucination | ▪ Visual impairment |
| ▪ Headache | ▪ Withdrawal syndrome |

There is a **dose-dependent risk** of serious harms associated with opioids.⁶

In **older people** and those with **renal impairment**, the risk and severity of adverse drug reactions is increased.^{2,4}

Long-term adverse effects^{4,5}

- Altered immune function
- Cognitive decline
- Dependence and addiction
- Endocrine abnormalities
- Falls (and fractures)
- Opioid induced hyperalgesia

Dependence and addiction is a significant risk for opioid use of >3 months duration.⁷

Drug-drug interactions associated with opioids^{4,5,8}

Interaction with serotonergic/antipsychotic drugs^{**}

Opioids interact with antidepressants and antipsychotics and can cause serotonin syndrome.

*Concomitant use of **tapentadol/tramadol** with serotonergic drugs, antipsychotics and other medicinal products that lower the seizure threshold, can induce convulsions.*

Interaction with CNS depressants^{**}

Opioids interact with CNS depressants and can produce additive CNS depressant effects, thereby increasing the risk of sedation, respiratory depression, coma and/or death.

There is a risk of potentially **fatal unintentional overdose** with opioid use.⁷

*Chronic pain is pain that lasts for more than three months.⁹⁻¹¹

**A full list of adverse drug reactions and drug interactions can be found in the individual SmPC available at www.hpra.ie.

This document should be used in conjunction with clinical judgement and decision making appropriate to the individual patient.

For further information on *Appropriate prescribing of opioids in the management of chronic non-cancer pain*, please refer to the full review available at www.hse.ie/yourmedicines.

- Chronic non-cancer pain (CNCP) may be caused by a number of different pathophysiologic mechanisms that may require different approaches to treatment.²
- The aim of treatment of CNCP is to reduce the impact of pain on quality of life, mood and function.⁵

Prior to initiating an opioid

- ✓ Optimise non-pharmacological treatments and non-opioid analgesics.¹²
- ✓ Consider that opioids are only effective to treat CNCP in a small percentage of people.¹
- ✓ Consider the **SERIOUS HARMS** associated with opioids.^{4,5}

Carefully select individuals for an opioid trial

- ✓ Develop the individual's understanding of chronic pain, how it differs from acute pain and the impact this may have on goals of therapy.^{13,14}
- ✓ Discuss the degree of pain relief that might be expected and that the aim is not complete pain relief but rather reducing pain sufficiently to engage in self-management.²
- ✓ Discuss potential **ADVERSE DRUG REACTIONS, LONG-TERM ADVERSE EFFECTS** of opioids and their ability to **IMPAIR DRIVING SKILLS**.^{2,4,5,7}
- ✓ Be aware that there is an ↑ risk and severity of adverse drug reactions with opioids in **OLDER PEOPLE** and those with **RENAL IMPAIRMENT**.^{2,4}
- ✓ Review the individual's medication history.

If initiating an opioid

- ✓ Agree realistic pain management goals with the individual.¹³
- ✓ Agree a treatment strategy and plan for discontinuation with the individual.⁷
- ✓ Prescribe the **LOWEST EFFECTIVE DOSE** as part of a trial.^{2,10,14,15}
- ✓ Use **SHORT-ACTING** opioids instead of extended release/long-acting opioids.¹⁴

Review

- ✓ Review prescriptions for opioids **REGULARLY**.²
- ✓ **REDUCE DOSE** when possible^{9,10}

Discontinue

- ✓ **DISCONTINUE** treatment if benefits in terms of meaningful improvements in pain and function do not outweigh significant risks or harms.¹³

For further information on *Appropriate prescribing of opioids in the management of chronic non-cancer pain*, please refer to the full review available at <https://www.hse.ie/yourmedicines>.

Points to consider when prescribing opioids

Only consider initiating an opioid for a **trial** to evaluate efficacy, tolerability and suitability in **carefully selected individuals**.^{2,10}

Prescribe at the **lowest effective dose**.^{10,14,15}

Set a **realistic treatment goal**.
*A realistic treatment goal is a 30% improvement in pain and/or a significant improvement in functional ability.*¹³

Consider that individuals who do not achieve useful pain relief from opioids within 2-4 weeks are **unlikely to gain benefit in the longterm**.²

Discontinue opioid treatment if the person is still in pain despite using opioids, **even if no other treatment is available**.²

References:

1. National Institute for Health and Care Excellence (NICE). Key Therapeutic Topics (KTT21). Medicines optimisation in chronic pain. January 2017 (updated 2019).
2. Faculty of Pain Medicine of the Royal College of Anaesthetists. Opioids Aware: A resource for patients and healthcare professionals to support prescribing of opioid medicines for pain.
3. British Medical Association (BMA). Chronic pain: Supporting safer prescribing of analgesics (2017).
4. Summary of Product Characteristics of individual opioids available at www.hpra.ie.
5. British National Formulary (BNF). March 2022.
6. Chou R, Turner JA, Devine EB et al. The effectiveness and risks of long-term opioid therapy for chronic pain: A systematic review for a National Institutes of Health Pathways to Prevention Workshop. *Ann Intern Med*. 2015; 162: 276-286.
7. Medicines and Healthcare products Regulatory Agency (MHRA). Drug Safety Update. Volume 14: Issue 2. September 2020.
8. Medicines and Healthcare products Regulatory Agency (MHRA). Drug Safety Update. Volume 13: Issue 8. March 2020.
9. National Institute for Health and Care Excellence (NICE). Chronic pain (primary and secondary) in over 16s: Assessment of all chronic pain and management of chronic primary pain. NICE Guideline 193. 2021.
10. Scottish Intercollegiate Guidance Networks (SIGN). Management of chronic pain. Guideline 136. 2013 (updated 2019).
11. The British Pain Society. Guidelines for Pain Management Programmes for adults. An evidence based review. 2013.
12. Häuser W, Morlion B, Vowles KE et al. European clinical practice recommendations on opioids for chronic noncancer pain-Part 1: Role of opioids in the management of chronic noncancer pain. *Eur J Pain*. 2021; 25: 949-968.
13. Scottish Government. Quality Prescribing for Chronic Pain. A Guide for Improvement 2018-2021.
14. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain-United States. *JAMA*. 2016; 315(15): 1624-1645.
15. International Association for the Study of Pain (IASP). IASP Statement. Opioids for Pain Management (February 2018).